Sunday, December 05, 2021 9:39:24 PM
The guidelines are pretty straightforward and just have to met. PPS of at least $2 for the capital market and $4 for the others. 4000:1 RS and you're sitting at over $13. Then you need capital, assets, income, whichever criteria you can meet, and having an underwriter who apparently put together a sales pitch to convince its clients that a share and a warrant for $10 was a worthy investment raising $23M minus their fees and profit worked out.
With a PPS entering NASDAQ north of $13 and over $20M in cash on the way, NASDAQ was easy.
NASDAQ is brutal, though, no more little fluffy PR's about patents, advisors, conferences, none of that matters, business performance is all that matters.
The O/S was roughly 900k after the RS. Should have been in the low 3M's after the offering, 3.5M at the most. Somehow it is sitting at 5.8M with over 5.5M unrestricted. Auctus and the other creditors were to get 2M units, but they weren't allowed to become a 5% owner, so it shouldn't be them that has raised the O/S already, they'd have to take small blocks and ease it in. They can begin to sell their stock in another week or two.
With a PPS entering NASDAQ north of $13 and over $20M in cash on the way, NASDAQ was easy.
NASDAQ is brutal, though, no more little fluffy PR's about patents, advisors, conferences, none of that matters, business performance is all that matters.
The O/S was roughly 900k after the RS. Should have been in the low 3M's after the offering, 3.5M at the most. Somehow it is sitting at 5.8M with over 5.5M unrestricted. Auctus and the other creditors were to get 2M units, but they weren't allowed to become a 5% owner, so it shouldn't be them that has raised the O/S already, they'd have to take small blocks and ease it in. They can begin to sell their stock in another week or two.
I swear I’ll never use the phrase “you can’t make this stuff up” ever again after being on the OTC. Apparently you can.
Recent BRTX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
- BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/23/2026 09:50:39 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 09:12:24 PM
- BioRestorative Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/14/2026 01:30:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/13/2026 02:48:15 PM
- BioRestorative Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/12/2026 03:30:00 AM
- BioRestorative Announces Positive Outcome from Type B Meeting with FDA • GlobeNewswire Inc. • 02/11/2026 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/10/2026 10:20:59 PM
- BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:31:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/12/2025 10:11:16 PM
